|
Abnormality of metabolism/homeostasis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Acute heart failure
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Plasma XOR activity was extremely high in patients with severely decompensated AHF.
|
30620450 |
2019 |
|
Acute kidney injury
|
0.200 |
Therapeutic
|
disease |
RGD |
Nephroprotective efficacy of chrysin against cisplatin-induced toxicity via attenuation of oxidative stress.
|
22571266 |
2012 |
|
Acute kidney injury
|
0.200 |
Therapeutic
|
disease |
RGD |
Mannitol attenuates kidney damage induced by xanthine oxidase-associated pancreas ischemia-reperfusion.
|
19628223 |
2010 |
|
Acute Lung Injury
|
0.200 |
Therapeutic
|
disease |
RGD |
Upregulation of xanthine oxidase by lipopolysaccharide, interleukin-1, and hypoxia. Role in acute lung injury.
|
9655743 |
1998 |
|
Adenine phosphoribosyltransferase deficiency
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this pilot study was to compare the effect of the xanthine oxidoreductase inhibitors allopurinol and febuxostat on urinary 2,8-dihydroxyadenine (DHA) excretion in APRT deficiency patients.
|
29241594 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, high tumoral XDH expression is an independent predictor of a poor prognosis in patients with adenocarcinoma of the lung.
|
22678977 |
2012 |
|
Adult Meningioma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, the same GPX1 polymorphisms and XDH rs7574920 were found to significantly modify the association between cumulative lead exposure and meningioma.
|
19505917 |
2009 |
|
Alcohol abuse
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Alcohol abuse is associated with enhanced pulmonary and systemic xanthine oxidoreductase activity.
|
28839105 |
2017 |
|
Alcohol Use Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
XOR protein in BAL cells from AUD subjects was increased in parallel with COX-2 expression, and furthermore, mRNA expression of NLRP3 inflammasome components was sustained in LPS-stimulated BAL cells from AUD subjects in conjunction with increased IL-1β.
|
28839105 |
2017 |
|
Alopecia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic prediction of male pattern baldness.
|
28196072 |
2017 |
|
Amyotrophic Lateral Sclerosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
New Strategy That Delays Progression of Amyotrophic Lateral Sclerosis in G1H-G93A Transgenic Mice: Oral Administration of Xanthine Oxidoreductase Inhibitors That Are Not Substrates for the Purine Salvage Pathway.
|
27815397 |
2016 |
|
Anaplastic carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
|
Animal Mammary Neoplasms
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
|
Anoxia
|
0.020 |
Biomarker
|
phenotype |
LHGDN |
Mechanisms underlying erythrocyte and endothelial nitrite reduction to nitric oxide in hypoxia: role for xanthine oxidoreductase and endothelial nitric oxide synthase.
|
18818408 |
2008 |
|
Anoxia
|
0.020 |
AlteredExpression
|
phenotype |
LHGDN |
We conclude that the transcription or translation of XOR is not influenced by hypoxia or hyperoxia.
|
12637268 |
2003 |
|
Apraxia, Developmental Verbal
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The prevalence rate of CAS was increased with increasing XOR activity.
|
29936631 |
2019 |
|
Arterial thrombosis
|
0.200 |
Therapeutic
|
phenotype |
RGD |
Role of xanthine oxidoreductase in the anti-thrombotic effects of nitrite in rats in vivo.
|
26374946 |
2016 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
During the past 10 years, evidence has mounted to support a role for XOR in the pathophysiology of inflammatory diseases and atherosclerosis as well as its previously determined role in ischemia-reperfusion injury.
|
11154741 |
2000 |
|
Arteriosclerosis
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that genetic variations in XDH contribute partly to hypertension and its complications, including atherosclerosis and CKD.
|
18712049 |
2008 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
We investigated the role of xanthine oxidoreductase (XOR) in atherosclerosis development, and the effects of the XOR inhibitor allopurinol on this process.
|
22095983 |
2012 |
|
Asthma
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
[Enzymes of purine metabolism of lymphocytes and eosinophiles in bronchial asthma].
|
12774669 |
2003 |
|
Atherosclerosis
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that genetic variations in XDH contribute partly to hypertension and its complications, including atherosclerosis and CKD.
|
18712049 |
2008 |
|
Atherosclerosis
|
0.030 |
GeneticVariation
|
disease |
LHGDN |
Our results suggest that genetic variations in XDH contribute partly to hypertension and its complications, including atherosclerosis and CKD.
|
18712049 |
2008 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
During the past 10 years, evidence has mounted to support a role for XOR in the pathophysiology of inflammatory diseases and atherosclerosis as well as its previously determined role in ischemia-reperfusion injury.
|
11154741 |
2000 |